The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Treatment with tirzepatide demonstrated a 38% decrease in the risk of heart failure outcomes (composite endpoint) compared with placebo. Detailed results were announced from the phase 3 SUMMIT trial ...